Paul Maciocia
8Patents
1h-index
5Co-inventors
36Inventor score
Filing activity: Jul 24, 2017 → Jun 3, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10730942B2 | Protein-based T-cell receptor knockdown | Chemistry; Metallurgy | 11 | Active |
| US11982673B2 | Methods | Chemistry; Metallurgy | 0 | Active |
| US11885807B2 | Method for depleting malignant T-cells | Chemistry; Metallurgy | 0 | Active |
| US11982672B2 | Methods | Chemistry; Metallurgy | 0 | Active |
| US11945867B2 | T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody | Physics | 0 | Active |
| US12221482B2 | Protein-based T-cell receptor knockdown | Chemistry; Metallurgy | 0 | Active |
| US11885806B2 | Method for depleting malignant T-cells | Chemistry; Metallurgy | 0 | Active |
| US11385233B2 | Methods of depleting malignant T-cells | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.